

Te Mātāpuna O Te Ora

The source of wellbeing Kia kotahi te hoe - Paddle in unison



Health New Zealand Te Whatu Ora Te Pae Hauora o Ruahine o Tararua MidCentral

PRIMARY CARE PRACTITIONER ADHD SPECIAL AUTHORITY RENEWAL APPLICATION FOR METHYLPHENIDATE

For patients age 18 years and over

IF CLIENT PRESENTS WITH ACUTE CONCERNS AND/OR RISK, PLEASE CALL 0800 653 357.										
Person Details	Surname:		Given name:							
	NHI:		D.O.B:							
	Ethnicity:		Contact number:							
	Allergies:		Contact email:							
	Referrer nan	ne:	Referrer phone:							
_			Referrer email:							
	Medication f	or S.A/CHEM Number:	Expiry date:							
The GP or NP prescribing methylphenidate is responsible for ongoing evaluation and monitoring of the person receiving treatment. This includes assessment of physical health and side effects from methylphenidate, effectiveness of treatment and assessment of risk of medication diversion.										
For further information about assessment and monitoring of medications used to treat ADHD, please go to: What is ADHD ADHD NZ - ADHD NEW ZEALAND ADHD Association Inc. • Healthpoint										
For queries or advice about ADHD management options please contact Specialist Primary Mental Health and Addiction Services on: MHASSPNon-UrgentGPQuery@midcentraldhb.govt.nz										
Was the diagnosis of ADHD made by a MidCentral clinician?		If yes - please give year and name of clinician if known: If no - please attach a previous paediatric/mental health specialist letter regarding the diagnosis. If the								
	Yes No	diagnostic assessment is available, please s If there is no diagnosis or paediatrics/ment Primary MH & Addiction team to discuss on MHASSPNon-UrgentGPQuery@midcentraldh	al health specialist letter, please contact the Specialist :							
What dose and formulation of medication is the person taking?										
Has the dose of formulation changed since the last renewal? Yes No If yes - what changes have been made? Yes No										
he syı	the edication Iping with mptoms ADHD? Yes No	Please describe:								

Have there been side effects of concern? Yes No	If yes -	please de	escribe (r	mood	changes	s, irritabi	ility, weig	ght loss, p	palpitatio	ons, tachy	vcardia, o.	r fainting	r.)
Are there any concerns regarding diversion or misuse?	If yes -	please de	escribe:										
Yes No													
Please give furth			/emotiona	ii/ pnysi	cai/socid	ai/ramily	nistory (etc & atto	acn as mu	еп ѕиррк	ementary	intormati	on as possible):
Outcome renew			Yes	No									
Reason for non-approval:	Describ	oe:											
Approving or no name/signature	n-appro and do	oving cons ate of app	sultant roval:										

This form when completed should be scanned and sent to referrer on outcome.

GP or NP can complete special authority renewal
on receipt of this form if request is approved by consultant.

MDHB-8570 Ver 2 2024 INT C: 3167 page 2 of 2